Management of Hot Flashes in a 77-Year-Old Man with Primary Hypogonadism
This patient has primary (hypergonadotropic) hypogonadism causing his hot flashes, and you should initiate testosterone replacement therapy after discussing potential benefits, harms, and costs with him, then reassess symptoms within 12 months. 1, 2
Diagnostic Interpretation
Your patient's laboratory results clearly indicate primary hypogonadism:
- Low testosterone (123 ng/dL; normal >300 ng/dL) and low free testosterone (1.1 ng/dL)
- Elevated LH (16.1) and FSH (19.3) indicate the pituitary is appropriately responding to low testosterone by increasing gonadotropin production
- Normal TSH and prolactin exclude thyroid dysfunction and hyperprolactinemia as causes
- This pattern represents testicular failure rather than age-related decline 1
The elevated gonadotropins distinguish this from simple age-related testosterone decline, where gonadotropins are typically normal or only mildly elevated. This is true primary hypogonadism requiring treatment consideration 1, 3.
Treatment Approach
Initial Discussion and Decision
Discuss testosterone therapy initiation focusing on 2:
- Potential benefits: Improvement in hot flashes (vasomotor symptoms), sexual function, energy, body composition
- Potential harms: Prostate monitoring requirements, cardiovascular considerations (though evidence is mixed), polycythemia risk
- Cost considerations: Intramuscular formulations are significantly less expensive than transdermal with similar efficacy 2
Recommended Formulation
Prefer intramuscular testosterone over transdermal preparations 2:
- Substantially lower cost
- Similar clinical effectiveness and safety profile
- Typical dosing: testosterone cypionate or enanthate 100-200 mg every 2 weeks, or 75-100 mg weekly
Monitoring Protocol
Within 12 months of initiation 2:
- Reassess hot flashes and other hypogonadal symptoms
- Discontinue therapy if no improvement in symptoms
- Check testosterone levels to ensure adequate replacement (target mid-normal range)
- Monitor hematocrit for polycythemia
- Assess prostate health (PSA, digital rectal exam if indicated)
Periodically thereafter: Continue symptom assessment and safety monitoring
Important Caveats
What NOT to Expect
The 2020 ACP guideline specifically recommends against initiating testosterone solely to improve energy, vitality, physical function, or cognition in age-related low testosterone 2. However, your patient has primary hypogonadism with clear pathology (testicular failure evidenced by elevated gonadotropins), not simple age-related decline, making him a more appropriate candidate.
Prostate Screening
Before initiating therapy, ensure:
- No history of prostate cancer
- Baseline PSA and consideration of digital rectal exam
- Understanding that testosterone doesn't initiate prostate cancer but requires monitoring
The Hot Flashes Connection
While not extensively discussed in guidelines, hot flashes in hypogonadal men are a recognized vasomotor symptom analogous to menopausal hot flashes in women. They result from testosterone deficiency affecting hypothalamic thermoregulation and typically improve with adequate testosterone replacement 4, 5.
Clinical Pitfall to Avoid
Do not dismiss this as simple "age-related" testosterone decline. The elevated gonadotropins (LH 16.1, FSH 19.3) are the key distinguishing feature indicating primary testicular failure rather than functional hypogonadism from aging or comorbidities 1. This patient has true organic hypogonadism warranting treatment consideration, not borderline age-related changes where the benefit-risk ratio is uncertain.